According to a StreetInsider report, Pfizer Inc. (NYSE:PFE) views Amarin Corporation plc (NasdaqGM:AMRN) and Vascepa as a good fit with its cardiovascular franchise and the Pfizer also has been looking for a potential blockbuster to replace its Lyrica nerve pain treatment before it goes off patent.
Market Closed -
Other stock markets
|
After market 16:22:41 | |||
30.03 USD | +1.80% |
|
30 | -0.12% |
08:31pm | Mark Cuban's Cost Plus to import penicillin to address US shortage | RE |
10:20am | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.31% | 167B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+2.52% | 125B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer Reportedly Eyes Amarin As A Potential Buyout Target